As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
Cannabis Industry
Cannabis Companies Demonstrate the Diverse Nature of the Global Marijuana Market
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
How InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Breakthrough Biosynthesis Works - Video
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
DOJA Cannabis Company Provides Production Update
DOJA Cannabis Company Limited (CSE: DOJA) is pleased to announce that we commenced cultivating our first cannabis strains in July and that the plants have taken well to their new home at DOJA's production facility in British Columbia's Okanagan Valley.
Cannabinoid Consumer Market Booming as CBD Enjoys Growth in Public Sentiment
As the cannabis industry continues to flourish, many publicly traded companies are finding ample opportunities to thrive.
At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles
Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available.
This Company Figured Out How to Make CBD from E. Coli
InMed Pharmaceuticals is making bacteria-bred cannabinoids “identical to those found in nature,” sans chemicals or even cannabis.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Attains $43M in Capital, Plans Significant Production Capacity Increase
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017.
CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017
CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development
The future of cannabinoid-based medicine hinges on such innovations which is: the ability to produce cannabinoids identical to those found in nature in a safe, consistent and economical fashion to advance cannabis-based drug development.
India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials
India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions.
Singlepoint, Inc. (SING) Singles Out Three More Reasons for Marijuana Mills to have Bank Accounts
Singlepoint, Inc. (OTC: SING) welcomed the recent request to the Financial Crimes Enforcement Network (FINCEN), by 10 senators, for further guidance ‘to financial institutions on their ability to provide services, specifically to indirect businesses that do nothing more than provide services to the state-sanctioned marijuana industry’.
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product.
For ChineseInvestors.com, Inc. (CIIX) Beauty is more than Just Skin Deep
ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line of hemp-infused skin care products in China. The cannabinoid content of the line makes these products more than just cosmetics.